Sorrento Therapeutics, Inc.

Symbol: SRNE

NASDAQ

0.014

USD

Market price today

  • -0.0174

    P/E Ratio

  • -0.0016

    PEG Ratio

  • 7.72M

    MRK Cap

  • 0.00%

    DIV Yield

Sorrento Therapeutics, Inc. (SRNE) Financial Statements

On the chart you can see the default numbers in dynamics for Sorrento Therapeutics, Inc. (SRNE). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Sorrento Therapeutics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003

balance-sheet.row.cash-and-short-term-investments

050126.956.5
22.5
159
20.9
83.5
136.4
71.9
31.7
5.1
3.5
5.3
3.4
0.4
0
0
0
0
0

balance-sheet.row.short-term-investments

026.390.20
0
0.3
0.4
1.1
97.4
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

024.518.715.5
14.5
4.4
3.9
3
2.6
0.7
0.4
0.1
0.1
0.2
0
0
0
0
0
0
0

balance-sheet.row.inventory

0108.11.8
3.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

03.17.53.7
27.2
16.2
4.9
3.2
2
1.3
0.6
0.1
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-current-assets

096.417386.2
67.6
179.6
29.7
89.7
141
73.9
32.6
5.3
3.6
5.6
3.5
0.4
0
0
0
0
0

balance-sheet.row.property-plant-equipment-net

0138.4126.573.9
76.3
24.4
19.3
12.7
7.2
2.3
2.4
1.5
1
0.1
0.1
0
0
0
0
0
0

balance-sheet.row.goodwill

080.379.543.6
38.3
38.3
38.3
41.5
20.6
24
24
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0136.9259.773.7
63.3
66.3
71
64.8
3.9
31
33.3
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0217.2339.2117.2
101.6
104.6
109.3
106.3
24.5
55
57.4
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

017.251.3256.4
262.2
265
270
189
170.1
10
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

03.74.82
49.9
50.6
3.3
3.9
0.6
0.3
0.1
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-non-current-assets

0376.5521.8449.6
490
444.5
401.9
311.9
202.5
67.6
60
1.5
1
0.1
0.1
0
0
0
0
0
0

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0472.8694.8535.8
557.6
624.1
431.6
401.6
343.5
141.5
92.6
6.8
4.6
5.7
3.6
0.4
0
0
0
0
0

balance-sheet.row.account-payables

047.527.424.7
27.6
13.8
9.9
8.3
1.3
1.7
2.2
0.4
0.2
0.2
0.3
0
0
0.5
0
0.1
0.1

balance-sheet.row.short-term-debt

030.243.526.8
39.6
10.2
0
0.2
4.8
3.3
0.4
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

0104.3194.1142.6
251.2
223.1
5.2
47.1
4.4
8.8
4.4
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

07.1118.9113.2
114.4
116.3
119.3
134.4
110.9
1.1
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0249.667.440.5
44.4
35
65.2
57.9
-86.2
3.5
3
0.1
0.1
0.2
0
0
0
0
0
0.2
0.2

balance-sheet.row.total-non-current-liabilities

0166.6477.2298.6
409.7
355
146
239
171.7
23.3
20.3
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

099.19553.9
55.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

0494.5616.7395.1
524.9
416.6
225
315.1
202.6
32.8
25.8
0.6
0.4
0.6
0.4
0
0
0.5
0
0.3
0.3

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

00.100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

0-1959.4-1386.6-958.3
-659.8
-367.8
-165.1
-174.3
-113.3
-67.5
-32.9
-11
-6.1
-2.9
-1.1
-1.7
-1.5
-1.2
-0.8
-1.1
-1.1

balance-sheet.row.accumulated-other-comprehensive-income-loss

01.510.5
-0.3
0
0.2
-0.1
73.6
-1.7
-0.9
-0.5
-0.2
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

01939.31464.31122.9
738.7
577.2
364.4
254.4
184.9
177.9
100.6
17.6
10.5
7.9
4.2
2.1
1.5
0.7
0.7
0.7
0.7

balance-sheet.row.total-stockholders-equity

0-18.678.7165.2
78.6
209.5
199.6
80
145.2
108.7
66.8
6.2
4.2
5.1
3.2
0.4
0
-0.5
0
-0.3
-0.3

balance-sheet.row.total-liabilities-and-stockholders-equity

0472.8694.8535.8
557.6
624.1
424.6
401.6
343.5
141.5
92.6
6.8
4.6
5.7
3.6
0.4
0
0
0
0
0

balance-sheet.row.minority-interest

0-3.1-0.6-24.4
-45.8
-2
0
6.5
-4.2
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

0-21.778.1140.7
32.8
207.5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

043.5141.5256.4
262.2
265.3
270.4
190.1
267.5
10
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

0134.5237.6169.4
290.8
233.3
5.2
47.3
9.2
12.1
4.8
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-debt

0110.9200.9112.9
268.3
74.5
-15.2
-35.1
-29.8
-59.8
-26.9
-5.1
-3.5
-5.3
-3.4
-0.4
0
0
0
0
0

Cash Flow Statement

The financial landscape of Sorrento Therapeutics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003

cash-flows.row.net-income

0-577.8-429.1-314.4
-363
-212.5
11.1
-63.9
-50.1
-34.7
-21.9
-4.8
-3.2
-1.8
-0.9
-0.2
-0.3
-0.4
0.3
0
0

cash-flows.row.depreciation-and-amortization

013.212.511
11
9.1
7.1
2.9
2.4
3.2
1.3
0.3
0.2
0
0
0
0
0
0
0
0

cash-flows.row.deferred-income-tax

0-1.8-35.9-2.1
-0.4
-6.1
-35.7
1
33.3
-1.7
0
0
3.2
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

074.890.231.4
12.6
6.2
5
4.7
7
3.9
1.8
0.9
0.3
0.3
0.1
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

069.6-2.83.8
7.2
6
-17.6
25.5
14.8
-0.2
0.4
-0.1
0
0
0.2
0
-0.5
0.4
-0.3
0
0

cash-flows.row.account-receivables

0-5.7-3-1.1
0
0
0
0
-0.2
0
0.1
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-9.58.610.2
0
0
0
0
7.8
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

09.9-3.9-3.7
10.2
3.6
1.6
3.7
-2.7
-0.5
0.9
0
0
-0.1
0.1
0
-0.5
0
0
0
0

cash-flows.row.other-working-capital

074.9-4.6-1.7
-3
2.4
-19.2
21.8
9.9
0.3
-0.6
-0.1
0
0.1
0
0
0
0
-0.3
0
0

cash-flows.row.other-non-cash-items

0128.183.4110.8
159.5
85.6
-69
-41.1
-49.5
0.7
1.9
0
-3.2
0
0
0
0.1
0
0
0
0

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-13.7-8.9-37.6
-11.4
-11.2
-11
-6.9
-3.7
-0.6
-0.9
-0.5
-1.1
0
0
0
0
0
0
0
0

cash-flows.row.acquisitions-net

0-14.9-36-2.3
-9.7
0
-5.6
-10.6
27.8
0
0.4
0
0
0
0.1
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0000
0
0
0
0
-11.5
-10
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

00124.80
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

0000
-17
-10
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

0-28.579.8-39.9
-38.2
-21.2
-16.5
-17.5
12.6
-10.6
-0.5
-0.5
-1.1
0
0.1
0
0
0
0
0
0

cash-flows.row.debt-repayment

0-188.3-85.7-205.6
-3.1
-45.7
-53.2
-9.5
-3.1
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

0402.3201.8317.9
47.7
83.6
57.9
108
0
71.8
37.7
5.9
2
3.4
4.1
0.6
0.7
0
0
0
0

cash-flows.row.common-stock-repurchased

000-55
0
0
0
-15.6
0
0
37701.4
5.9
0
4.2
6
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

097.765.2116.9
34.3
288.1
48.9
48.8
-0.3
7.8
-37695.5
-5.9
0
-4.2
-6
0
0
0
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

0311.7181.3174.2
78.9
326
53.7
131.7
-3.3
79.6
43.6
6
2
3.4
4.1
0.6
0.7
0
0
0
0

cash-flows.row.effect-of-forex-changes-on-cash

0-2.40.80.9
-0.3
-0.1
0.1
0
0
0
0
0
0
0
0.7
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

0-13-19.8-24.3
-132.6
192.9
-62
43.4
-32.9
40.2
26.6
1.6
-1.8
1.8
4.1
0.4
0
0
0
0
0

cash-flows.row.cash-at-end-of-period

023.636.756.5
80.8
213.3
20.4
82.4
39
71.9
31.7
5.1
3.5
5.3
3.4
0.4
0
0
0
0
0

cash-flows.row.cash-at-beginning-of-period

036.756.580.8
213.3
20.4
82.4
39
71.9
31.7
5.1
3.5
5.3
3.4
-0.7
0
0
0
0
0
0

cash-flows.row.operating-cash-flow

0-293.9-281.8-159.5
-173
-111.8
-99.2
-70.9
-42.1
-28.8
-16.5
-3.8
-2.7
-1.5
-0.7
-0.2
-0.7
0
0
0
0

cash-flows.row.capital-expenditure

0-13.7-8.9-37.6
-11.4
-11.2
-11
-6.9
-3.7
-0.6
-0.9
-0.5
-1.1
0
0
0
0
0
0
0
0

cash-flows.row.free-cash-flow

0-307.5-290.7-197.1
-184.4
-123
-110.2
-77.8
-45.8
-29.4
-17.4
-4.3
-3.8
-1.6
-0.8
-0.2
-0.7
0
0
0
0

Income Statement Row

Sorrento Therapeutics, Inc.'s revenue saw a change of NaN% compared with the previous period. The gross profit of SRNE is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003

income-statement-row.row.total-revenue

062.852.940
31.4
21.2
151.9
8.2
4.6
3.8
0.5
0.6
0.5
0.7
0
0
0
0
0
0
0

income-statement-row.row.cost-of-revenue

033.5139.9
12.2
7.1
3.9
0.8
1.9
2
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

029.439.930
19.2
14.1
147.9
7.3
2.6
1.8
0.5
0.6
0.5
0.7
0
0
0
0
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

04.34.14.1
3.9
3
2.6
0.8
1.2
2.3
0.8
0
0
0
0
0
0
0
-0.3
0
0

income-statement-row.row.operating-expenses

0407.9407.9231.6
214.4
143.6
96.5
67.2
52.6
36.3
16.1
5.4
3.8
2.5
1
0.2
0.2
0.4
-0.3
0
0

income-statement-row.row.cost-and-expenses

0441.3420.9241.5
226.6
150.7
100.4
68
54.6
38.4
16.1
5.4
3.8
2.5
1
0.2
0.2
0.4
-0.3
0
0

income-statement-row.row.interest-income

0000
1.1
0.9
0.2
0.3
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

08.610.220.2
36.1
57.6
5
1.6
1.7
1.6
0.3
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-183.2-94.5-109.1
-164.4
-63.4
-10
31.9
60.2
-1.6
-0.2
0
0
0
0
0
0
0
-0.3
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

04.34.14.1
3.9
3
2.6
0.8
1.2
2.3
0.8
0
0
0
0
0
0
0
-0.3
0
0

income-statement-row.row.total-operating-expenses

0-183.2-94.5-109.1
-164.4
-63.4
-10
31.9
60.2
-1.6
-0.2
0
0
0
0
0
0
0
-0.3
0
0

income-statement-row.row.interest-expense

08.610.220.2
36.1
57.6
5
1.6
1.7
1.6
0.3
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

014-15.49.7
12.1
9.1
7.1
2.9
2.4
3.2
1.3
0.3
0.2
0
0
0
0
0
0
0
0

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0-378.5-368-201.5
-195.2
-150.4
25.3
-96.8
-74
-34.7
-21.7
-4.9
-3.2
-1.8
-1
-0.2
-0.2
-0.4
-0.3
0
0

income-statement-row.row.income-before-tax

0-561.7-462.5-310.6
-359.6
-213.8
15.3
-64.8
-13.8
-36.4
-21.9
-4.8
-3.2
-1.8
-0.9
0
-0.3
0
-0.6
0
0

income-statement-row.row.income-tax-expense

0-2.4-33.5-2
-0.5
-6.3
-36
-0.9
36.3
-1.7
0
0
0
0
0
0
0
0.4
-0.3
0
0

income-statement-row.row.net-income

0-559.3-429-308.6
-359.1
-203.5
9.1
-60.9
-45.8
-34.7
-21.9
-4.8
-3.2
-1.8
-0.9
-0.2
-0.3
-0.4
-0.3
0
0

Frequently Asked Question

What is Sorrento Therapeutics, Inc. (SRNE) total assets?

Sorrento Therapeutics, Inc. (SRNE) total assets is 472840000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.416.

What is company free cash flow?

The free cash flow is -0.323.

What is enterprise net profit margin?

The net profit margin is -9.463.

What is firm total revenue?

The total revenue is -5.619.

What is Sorrento Therapeutics, Inc. (SRNE) net profit (net income)?

The net profit (net income) is -559331000.000.

What is firm total debt?

The total debt is 134504000.000.

What is operating expences number?

The operating expences are 407888000.000.

What is company cash figure?

Enretprise cash is 0.000.